Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA dynamic monitoring of PD-1 antibody plus chemotherapy in first-line advanced gastric cancer
ChiCTR2200065366Phase 3Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of PD-1 Monoclonal Antibody in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Dynamic changes of circulating tumor DNA before and after treatment. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
PD-1 Monoclonal Antibody
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200065366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065366.